Scientific Advisory Board · 2026

Advisors

Status: Scientific Advisory Board forming Q2 2026. Seats below are open. We are intentionally transparent that no SAB member has yet been confirmed — solo founder + named advisors is the credibility shape we are building toward. Outreach is in progress.

Open SAB seats

AAV gene therapy expert

Capsid engineering · payload design · CMC strategy · GMP manufacturing oversight

Profile: prior IND-enabling work on at least one AAV serotype, ideally with vendor relationships at academic core or CDMO scale. Spark / Sarepta / Voyager / Asklepios / Ultragenyx alumni preferred.

Ex-FDA CBER reviewer

Pre-IND strategy · briefing book · gene therapy-specific guidance · RMAT pathway

Profile: prior reviewer experience on gene therapy INDs, ideally familiar with the OTAT / RMAT framework. Independent consulting basis acceptable.

Tumor immunology PI

NKG2D / NK cell biology · MICA/MICB shedding · TME escape mechanisms

Profile: published primary work on NKG2D ligand biology in solid tumors, particularly the shedding/escape literature. Academic appointment at a major US cancer center preferred.

Computational biology / structural biology PI

AlphaFold-era construct design · validation methodology · benchmarking against wet-lab outcomes

Profile: PI-level experience using modern structural prediction in therapeutic design. Independent voice on the in silico package quality.

Engagement model

Quarterly working calls (60 min) with the founder
Asynchronous review of preprint drafts, regulatory documents, and study designs
Compensation: SAB equity grant (founder equity pool) + customary cash retainer at seed close
Non-exclusive — current academic appointments and other advisory roles are not a conflict
Term: 2 years renewable, 30-day mutual termination clause

How to engage

If your background fits any of the above (or you can recommend someone whose does), email advisors@nightboxllc.com. A two-paragraph note plus a one-page CV is enough; we respond to every credible note within 72 hours.

Why we are public about this

Most early-stage biotechs treat SAB recruitment as private and announce only after seats are filled. We are doing the opposite — publishing the gap, the criteria, and the reasoning — because (a) it forces our own discipline about who we actually need versus who we could superficially attract, (b) it gives candidates a clear honest read on the company stage, and (c) it lets our investors and partners see that we know our own limitations and are actively closing them.